NCT04142684 (ENMG-DIAPH) is a clinical trial in Unilateral Diaphragmatic Paralysis, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT04142684?

NCT04142684 is sponsored by Assistance Publique - Hôpitaux de Paris.

What condition does NCT04142684 study?

NCT04142684 studies Unilateral Diaphragmatic Paralysis.

Is NCT04142684 still recruiting?

NCT04142684 is currently completed. Last updated 28 September 2021.

Last reviewed 2021-09-28 · How we verify

NCT04142684: ENMG-DIAPH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phrenic Nerve Conduction Study to Diagnose Unilateral Diaphragmatic Paralysis

Completed Last updated 28 September 2021

What this trial tests

trial in Unilateral Diaphragmatic Paralysis in 28 participants. Completed in 24 February 2020.

Timeline

24 January 2020

Primary endpoint
24 February 2020

24 February 2020

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Status	Completed
Study type	OBSERVATIONAL
Enrollment	28
Start date	24 January 2020
Primary completion	24 February 2020
Estimated completion	24 February 2020
Sites	1 location across France

Conditions studied

Unilateral Diaphragmatic Paralysis — all drugs for Unilateral Diaphragmatic Paralysis →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Unilateral Diaphragmatic Paralysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims as the principal objective to compare two approaches to diagnosis unilateral diaphragmatic paralysis: transdiaphragmatic pressure (Pdi) measurement versus phrenic nerve conduction (NPC) study. The secondary objective of the study is the strengths and weaknesses of different tests. Diagnostic threshold values.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04142684 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 28 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04142684.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing